H A Austin

2.8k total citations · 1 hit paper
29 papers, 2.0k citations indexed

About

H A Austin is a scholar working on Rheumatology, Nephrology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, H A Austin has authored 29 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Rheumatology, 11 papers in Nephrology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in H A Austin's work include Systemic Lupus Erythematosus Research (16 papers), Renal Diseases and Glomerulopathies (10 papers) and Liver Diseases and Immunity (4 papers). H A Austin is often cited by papers focused on Systemic Lupus Erythematosus Research (16 papers), Renal Diseases and Glomerulopathies (10 papers) and Liver Diseases and Immunity (4 papers). H A Austin collaborates with scholars based in United States, Greece and United Kingdom. H A Austin's co-authors include James E. Balow, Dimitrios T. Boumpas, Ellen M. Vaughan, John H. Klippel, Cheryl Yarboro, A D Steinberg, Gabor G. Illei, P L Choyke, J Cady and M F Gourley and has published in prestigious journals such as The Lancet, Annals of Internal Medicine and Neurology.

In The Last Decade

H A Austin

29 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis

1992 579 citations Dimitrios T. Boumpas, H A Austin et al. The Lancet profile →

Peers

Countries citing papers authored by H A Austin

Since Specialization

Citations

This map shows the geographic impact of H A Austin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H A Austin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H A Austin more than expected).

Fields of papers citing papers by H A Austin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H A Austin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H A Austin. The network helps show where H A Austin may publish in the future.

Co-authorship network of co-authors of H A Austin

This figure shows the co-authorship network connecting the top 25 collaborators of H A Austin. A scholar is included among the top collaborators of H A Austin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H A Austin. H A Austin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment of lupus nephritis 2013 ·La Revue de Médecine Interne ·H A Austin, (unknown)	4
2	Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis 2007 ·Lara D. Veeken ·Gabor G. Illei, Cheryl Yarboro, Takashi Kuroiwa, Ryan Schlimgen, H A Austin, John F. Tisdale, Puja Chitkara, Thomas A. Fleisher, John H. Klippel, James E. Balow, Dimitrios T. Boumpas	18
3	Nephrotic syndrome: an under‐recognised immune‐mediated complication of non‐myeloablative allogeneic haematopoietic cell transplantation 2005 ·British Journal of Haematology ·Ramaprasad Srinivasan, James E. Balow, Sharda G. Sabnis, Andreas Lundqvist, Takehito Igarashi, Yoshiyuki Takahashi, H A Austin, John F. Tisdale, John Barrett, Nancy L. Geller, Richard Childs	49
4	Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura 2004 ·American Journal of Hematology ·Margaret E. Rick, H A Austin, Susan F. Leitman, (unknown), David L. Aronson	16
5	Shaping the future of shared governance. 2002 ·PubMed ·H A Austin, (unknown)	1
6	Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: Long‐term followup of a cohort of 145 patients participating in randomized controlled studies 2002 ·Arthritis & Rheumatism ·Gabor G. Illei, Kazuki Takada, Donald Maxwell Parkin, H A Austin, Marianna Crane, Cheryl Yarboro, Ellen M. Vaughan, Takashi Kuroiwa, Carol L. Danning, (unknown), A D Steinberg, M F Gourley, John H. Klippel, James E. Balow, Dimitrios T. Boumpas	236
7	Impaired renal function in progressive multiple sclerosis 2002 ·Neurology ·Peter A. Calabresi, H A Austin, Michael K. Racke, Andrew Goodman, P L Choyke, Heidi Maloni, Henry F. McFarland	23
8	New prospects for treatment of lupus nephritis. 2000 ·PubMed ·James E. Balow, Dimitrios T. Boumpas, H A Austin	16
9	Natural history and treatment of lupus nephritis. 1999 ·PubMed ·H A Austin, James E. Balow	35
10	Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS 1998 ·Neurology ·Peter A. Calabresi, (unknown), Heidi Maloni, (unknown), J A Carlino, Jeff Moore, Michael C. Levin, Suhayl Dhib‐Jalbut, Laura R. Tranquill, H A Austin, H. F. McFarland, Michael K. Racke	95
11	Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus. 1997 ·PubMed ·H A Austin, (unknown), (unknown), Dimitrios T. Boumpas, James E. Balow	14
12	High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients 1995 ·Nephrology Dialysis Transplantation ·H A Austin, Dimitrios T. Boumpas, Ellen M. Vaughan, James E. Balow	173
13	A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus. 1994 ·PubMed ·(unknown), Thomas A. Fleisher, (unknown), Michael Brown, Vibeke Strand, H A Austin, James E. Balow, (unknown)	18
14	Membranous Nephropathy 1992 ·Annals of Internal Medicine ·H A Austin, Tatiana T. Antonovych, Karen Mackay, DT Boumpas, James E. Balow	31
15	Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis breakdown → 1992 ·The Lancet ·Dimitrios T. Boumpas, H A Austin, James E. Balow, Ellen M. Vaughan, Cheryl Yarboro, John H. Klippel, A D Steinberg	579
16	Dynamic Gd-DTPA-enhanced MR imaging of the kidney: experimental results. 1989 ·Radiology ·Peter L. Choyke, Joseph A. Frank, Mary Girton, (unknown), Mark J. Carvlin, (unknown), H A Austin, Andrew J. Dwyer	97
17	Chronic Dialysis in a Patient with Cystic Fibrosis 1989 ·The Nephron journals/Nephron journals ·C. Rotellar, Monica Mazzoni, H A Austin, Sharda G. Sabnis, Lucas L. Kulczycki, Thomas A. Rakowski, (unknown), (unknown)	5
18	Cyclosporin A in Severe, Treatment-Refractory Rheumatoid Arthritis 1988 ·Annals of Internal Medicine ·David E. Yocum, John H. Klippel, R L Wilder, Lynn H. Gerber, H A Austin, Sharon M. Wahl, Lynna M. Lesko, (unknown), Harry G. Preuss, Cheryl Yarboro, (unknown), (unknown)	105
19	Studies of Immunosuppressive Drugs in the Treatment of Lupus Nephritis 1987 ·Rheumatic Disease Clinics of North America ·John H. Klippel, H A Austin, James E. Balow, (unknown), A D Steinberg, Paul H. Plötz, John L. Decker	15
20	Glioblastoma: catheter techniques for isolated chemotherapy perfusion. 1986 ·Radiology ·J L Doppman, Robert L. Dedrick, (unknown), Robert J. Lutz, (unknown), J. Bob Blacklock, J Boretos, (unknown), H A Austin, Robert L. Bowman	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact